| abstract |
The disclosure relates to vitamin D analogs represented by formulae (IIA) & (IIB), particularly disclosed is (20R,25S)-2-Methylene-19,26-dinor-1alpha,25-dihydroxyvitamin D3 (NEL) and pharmaceutical formulations that include this compound. The disclosure also relates to the use of NEL or salts thereof in the preparation of medicaments for use in treating various diseases selected from psoriasis; leukemia; colon cancer; breast cancer; prostate cancer; multiple sclerosis; lupus; diabetes mellitus; host versus graft reaction; rejection of organ transplants; an inflammatory disease selected from rheumatoid arthritis, asthma, or inflammatory bowel diseases; a skin condition selected from wrinkles, lack of adequate skin firmness, lack of adequate dermal hydration, or insufficient sebum secretion; renal osteodystrophy; vitamin D-resistant rickets; osteoporosis; or psoriatic arthritis |